London, May 13, 2026, 16:01 BST
- On May 12, Reckitt snapped up 208,000 shares, paying a volume-weighted average of 4,560.89 pence each.
- This marks another move in the third tranche under the £1 billion buyback program.
- Shares slipped 0.85% in London, hovering near the stock’s 52-week low.
Reckitt Benckiser Group plc snapped up 208,000 of its own shares, sticking with its capital-return strategy as the shares hover close to a one-year low, according to a regulatory filing published Wednesday. The Dettol, Durex and Mucinex owner bought the stock from Deutsche Bank AG, London Branch, paying between 4,534 pence and 4,581 pence per share. The repurchased shares go into treasury, so they’ll stay on Reckitt’s books instead of moving to outside holders.
Timing’s key here. Reckitt’s buyback stands out as a rare source of support for shareholders, especially after a shaky first quarter soured sentiment on the consumer-health group’s 2026 goals.
The shares were last seen at 4,534 pence on the sell side and 4,536 pence to buy according to AJ Bell’s delayed London market feed, slipping 0.85%. That keeps the price hovering just above a 52-week low of 4,524 pence, with a market value around £29.04 billion.
This latest buy falls under the third part of Reckitt’s £1 billion share buyback program. Back in March, Reckitt said this tranche—overseen by Deutsche Bank—would return up to £540 million to shareholders, starting March 9 and wrapping up no later than July 27.
While buybacks shrink the share count and can boost earnings per share, they don’t address sluggish demand, rising input costs, or uncertainty about growth rates.
Reckitt’s April first-quarter update was something of a mixed bag for investors. Chief Executive Kris Licht reported, “Core Reckitt delivered Q1 LFL net revenue growth of 1.3%,” citing the industry’s preferred metric—stripping out currency swings and portfolio moves to get a true year-on-year read. Licht pointed to weaker illness trends, sluggish demand in Europe, and geopolitical headwinds, but left the 2026 like-for-like revenue guidance where it was. Reckitt
Investors didn’t get what they were hoping for. According to Reuters, Reckitt posted 1.3% core like-for-like growth—well below the 2.9% analysts had penciled in. The company also flagged that first-half margins would drop by around 200 basis points compared to last year. Harsharan Mann at Aviva Investors described the period as “broad-based muted growth.” Over at JPMorgan, analyst Celine Pannuti said the latest numbers put Reckitt’s ability to reach full-year goals in question. Reuters
The broader peer group didn’t offer much support. Haleon, which makes Sensodyne and Panadol, slipped 1.16% in London trading, and Unilever edged down 0.36%, AJ Bell data showed. Reckitt shares fell harder than Unilever, but didn’t drop quite as far as Haleon. That left Reckitt stuck in the weak UK consumer-health and staples pack.
There’s a risk that pressure could spill into the second half as well. Lingering oil-driven cost issues, continued Middle East disruptions, sluggish cold-and-flu demand, or China’s tax move affecting condoms—all could mean the buyback won’t be enough to calm new worries about margins and sales.
Thursday brings a different kind of event for investors: Reckitt will host its online “Focus On: Digital Science” session from 15:00 BST to 17:00 BST. This isn’t a results update, but with shares hovering close to a 12-month low, the market will be combing for anything on efficiency, innovation, or data-driven growth. Reckitt
